StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Cardiovascular, Renal & Metabolism (CVRM) by Quarter

Cardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Cardiovascular, Renal & Metabolism (CVRM): $887M in Q2 2026, down 0.2% from a year earlier.

Latest, Q2 2026
887
Period ended Jun 30, 2026
Change on a year earlier
-0.2%
889 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| CVRM | 2,771 | | ( 15 ) | | ( 18 ) | | 375 | | ( 44 ) | | 1,346 | | ( 11 ) | | ( 15 ) | | 887 | | - | | ( 4 ) | | 163 | | ( 16 ) | | ( 12 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Therapy Area Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026887-0.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026868+7.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025895+1.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025806-2.4%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025889+5.5%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025807+12.7%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024886+30.5%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024826+25.7%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024843+38.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024716+28.5%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023679+37.7%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023657+40.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023611+32.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023557+15.6%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022493+27.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022469+23.1%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up cardiovascular, Renal & Metabolism (CVRM)

Cite this data

StockData. (2026). AstraZeneca Cardiovascular, Renal & Metabolism (CVRM) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-cvrm-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.